Currently Akt (MK2206) and mTOR (Temsirolimus) inhibitors are being evaluated in clinical trials for patients with various forms of cancer including prostate cancer (NCT01480154, 00919035). The gene discussed is MTOR; the disease is prostate carcinoma.